Home - Australian Pharmacist

Vyvanse® (lisdexamfetamine dimesilate) for treatment of adults with ADHD

Takeda Medical - February 25, 2021

Advertorial

Vyvanse® (lisdexamfetamine dimesilate) for treatment of adults with ADHD: PBS listed from 1 February 20211,2

PSA welcomes new (and re-elected) branch committee members

Chloe Hava - May 19, 2021

Alicia Martin MPS has joined the PSA ACT Branch Committee.

People

A number of new PSA State and Territory Branch leaders were elected this month. Australian Pharmacist spoke to three new recruits about their hopes for the profession.

Guidance and advice: PSA’s new practice expert

Jennifer Cooke - August 26, 2020

PSA's new practice expert Amanda Fairjones MPS.

People

From compounding to COVID-19, Amanda Fairjones BPharm Hons AACPA, MPS can get answers for all your member queries.

Pharmacists’ skills showcased at Parliament House

Peter Guthrey FPS - October 8, 2025

Industry

Yesterday (Tuesday 7 October), PSA, in a joint event with Consumer Healthcare Products Australia (CHP Australia), showcased the breadth of pharmacists’ skills and roles...

Oral PDE4 inhibitors in the management of stable COPD

Dr Hanan Khalil - November 1, 2017

Clinical

Almost 1.45 million Australians have some form of chronic obstructive pulmonary disease (COPD). This equates to one in seven Australians over 40 suffering from...

Quantifying drug loss while crushing tablets

Sharon Smith - July 9, 2018

Clinical

Up to 42% of an active drug can be lost through common crushing activities, a study comparing devices and methods has found. Via a validated...

1...122123124...317 Page 123 of 317

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

So what about the Rikodeine?

Table 1 – Legal requirements for pharmacists when prescribing Schedule 3 medicines

References

What motivated you to seek election as the next PSA National President?

What do you hope to achieve as PSA President?

Why do you feel this is such a pivotal moment for PSA and the profession?

What are the major challenges pharmacists are facing right now?

How do you see the profession evolving in 5 years?

How have your background and previous experiences shaped your views of the profession?

Case scenario

Learning objectives

Introduction

Aetiology and pathophysiology

Clinical features

Diagnosis, differential diagnosis and prognosis

Management and treatment

Knowledge to practice

Conclusion

Case scenario continued

Key points

References

Our authors

Our reviewer

Conflict of interest declaration

Wrong-patient supply leads to hospital admission

Labelling and selection errors

A stronger incident-reporting culture

Building a career in incident management

ALERT 1: Potential risk of suicidal thoughts

What does the product warning say?

What products are affected by this alert?

What should pharmacists do?

ALERT 2: Tirzepatide (Mounjaro) and contraception

Is it just tirzepatide (Mounjaro)?

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

So what about the Rikodeine?

Table 1 – Legal requirements for pharmacists when prescribing Schedule 3 medicines

References

What motivated you to seek election as the next PSA National President?

What do you hope to achieve as PSA President?

Why do you feel this is such a pivotal moment for PSA and the profession?

What are the major challenges pharmacists are facing right now?

How do you see the profession evolving in 5 years?

How have your background and previous experiences shaped your views of the profession?

Case scenario

Learning objectives

Introduction

Aetiology and pathophysiology

Clinical features

Diagnosis, differential diagnosis and prognosis

Management and treatment

Knowledge to practice

Conclusion

Case scenario continued

Key points

References

Our authors

Our reviewer

Conflict of interest declaration

Wrong-patient supply leads to hospital admission

Labelling and selection errors

A stronger incident-reporting culture

Building a career in incident management

ALERT 1: Potential risk of suicidal thoughts

What does the product warning say?

What products are affected by this alert?

What should pharmacists do?

ALERT 2: Tirzepatide (Mounjaro) and contraception

Is it just tirzepatide (Mounjaro)?

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

**ALERT 2: Tirzepatide (Mounjaro) and contraception**

**ALERT 2: Tirzepatide (Mounjaro) and contraception**

**ALERT 2: Tirzepatide (Mounjaro) and contraception**